Literature DB >> 6932998

Pulmonary alveolar proteinosis complicating chronic myelogenous leukemia.

D Green, P Dighe, N O Ali, G V Katele.   

Abstract

Pulmonary alveolar proteinosis (PAP) has been reported in 5 patients with chronic myelogenous leukemia and approximately 20 patients with other hematologic malignancies. These patients have had recurrent infections, frequently by opportunistic organisms. This susceptibility suggests that they have impaired cell-mediated immunity. In the case reported, splenectomy early in the course of illness may have contributed to the susceptibility to infection and PAP. Awareness of the possibility of pulmonary alveolar proteinosis in a patient with progressive dyspnea and unexplained pulmonary infiltrates should prompt early open lung biopsy to establish the diagnosis. Therapeutic pulmonary lavage is currently the treatment of choice.

Entities:  

Mesh:

Year:  1980        PMID: 6932998     DOI: 10.1002/1097-0142(19801015)46:8<1763::aid-cncr2820460811>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

Review 1.  Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis.

Authors:  P L Shah; D Hansell; P R Lawson; K B Reid; C Morgan
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

Review 2.  The molecular basis of pulmonary alveolar proteinosis.

Authors:  Brenna Carey; Bruce C Trapnell
Journal:  Clin Immunol       Date:  2010-03-25       Impact factor: 3.969

Review 3.  Secondary alveolar proteinosis in cancer patients.

Authors:  S Ladeb; J Fleury-Feith; E Escudier; J Tran Van Nhieu; J F Bernaudin; C Cordonnier
Journal:  Support Care Cancer       Date:  1996-11       Impact factor: 3.603

4.  Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression.

Authors:  U Dirksen; R Nishinakamura; P Groneck; U Hattenhorst; L Nogee; R Murray; S Burdach
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.